About this content About Emily Jarvie Emily began her career as a political journalist for Australian Community Media in Hobart, Tasmania. After she relocated to Toronto, Canada, she reported on business, legal, and scientific developments in the emerging psychedelics sector before joining Proactive in 2022. She brings a strong journalism background with her work featured in newspapers, magazines, and digital publications across Australia, Europe, and North America, including The Examiner, The Advocate, ...

Core Insights - Hyundai Bioscience has announced a significant advancement in its antiviral strategy with the introduction of Xafty, a broad-spectrum antiviral drug, aimed at addressing multiple viral infections simultaneously [1][2][4] Company Strategy - The company has unveiled a "One Drug, Two Tracks" strategy, targeting Dengue in Vietnam and respiratory viruses (Flu, COVID, RSV) in the U.S. using the same drug [1][4] - The clinical strategy was developed in collaboration with Dr. Davey Smith, a prominent figure in the field of medicine [2][4] Clinical Development - Hyundai Bioscience is entering Phase 2 clinical trials in the U.S. for Xafty, which is based on niclosamide and modified for enhanced bioavailability [1][6] - The company is prepared to submit its Investigational New Drug (IND) application to the FDA immediately [5] Market Context - Dr. Smith has identified the current U.S. healthcare crisis as a "tripledemic" involving Influenza, RSV, and COVID-19 variants, highlighting the need for a unified treatment approach [3][4] - The "Basket Trial" design of Xafty is presented as an efficient solution to combat the multi-viral crisis [4] Vision for the Future - The company envisions 2026 as a pivotal year for public health, aiming to shift from reactive to pre-emptive measures against viral infections [5]

Core Insights - NanoViricides, Inc. announced that its clinical lead drug NV-387 has demonstrated strong efficacy against the Measles virus in a humanized animal model [1] - The company is preparing to make NV-387 available for emergency use application in response to ongoing Measles outbreaks [1] Company Summary - NanoViricides, Inc. is a publicly traded company listed on NYSE American under the ticker NNVC [1] - The company focuses on developing antiviral therapies, with NV-387 being a significant advancement in its pipeline [1] Industry Context - The announcement comes amid a rising number of Measles outbreaks, highlighting the urgent need for effective treatments [1] - The potential emergency use of NV-387 could position the company as a key player in addressing public health challenges related to viral infections [1]

Group 1 - Proactive provides fast, accessible, informative, and actionable business and finance news content to a global investment audience [2] - The news team covers medium and small-cap markets, as well as blue-chip companies, commodities, and broader investment stories [3] - Proactive has a presence in key finance and investing hubs with bureaus and studios located in London, New York, Toronto, Vancouver, Sydney, and Perth [2][3] Group 2 - The company is committed to using technology to enhance workflows and has adopted various technological tools [4] - Proactive employs automation and software tools, including generative AI, while ensuring all content is edited and authored by humans [5]